Results 191 to 200 of about 6,899,630 (383)

Evolutionary radiation of large‐bodied gorgonopsians from the lower Abrahamskraal formation of South Africa

open access: yesThe Anatomical Record, EarlyView.
Abstract The middle Permian represents a critical interval in therapsid evolution, when gorgonopsians emerged as some of the first specialized apex predators within terrestrial ecosystems. Despite their significance, the early diversification of Gorgonopsia in Gondwana remains poorly understood due to scarcity and fragmentary material.
Zanildo Macungo   +5 more
wiley   +1 more source

Compensation Response to Hepatic Gluconeogenesis via β‐Hydroxybutyrylation of FBP1 and PCK1 in Dairy Cows

open access: yesAnimal Research and One Health, EarlyView.
(1) Kbhb modification of FBP1 and PCK1 is involved in regulation of the gluconeogenesis pathway. (2) Kbhb of FBP1 and PCK1 is catalyzed by p300 and removed by HDACs. (3) BHB induced an increase in the enzymatic activity of FBP1 and PCK1 through Kbhb modification at the K43 site of FBP1 and the K191 site of PCK1.
DingPing Feng   +6 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy